Longitudinal observation on CSF Aβ42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice

被引:33
作者
Liu, L
Herukka, SK
Minkeviciene, R
van Groen, T
Tanila, H
机构
[1] Univ Kuopio Canthia, Dept Neurosci & Neurol, Kuopio 70211, Finland
[2] Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA
[3] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland
基金
芬兰科学院;
关键词
Alzheimer's disease; amyloid; cerebrospinal fluid; transgenic mouse; hippocampus;
D O I
10.1016/j.nbd.2004.08.005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
To relate levels of beta-amyloid,12 (Abeta42) in the cerebrospinal fluid (CSF) and brain in early Alzheimer's disease, we repeatedly measured CSF Abeta42 levels in transgenic mice carrying Swedish amyloid precursor protein and presenilin-1 mutations, at ages before and after amyloid deposition. Hippocampal Abeta42 levels were measured at the endpoints. In APPswe/PS1(A246E) mice, CSF Abeta42 levels significantly increased between 5 and 7 months of age but did not change between 8 and 13 months despite a rapid increase in brain Abeta42. Furthermore, a decline in CSF Abeta42 levels was observed between 6 and 9 months in APPswe/ PS1dE9 mice with faster pathology. Interestingly, the initial CSF Abeta42 concentrations correlated more strongly with brain Abeta42 levels than the endpoint CSF Abeta42. Our results suggest that the levels of CSF Abeta42 initially reflect the rate of Abeta42 production, but after reaching a critical concentration stay in equilibrium, until plaque formation leads to decreased CSF Abeta42 levels. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:516 / 523
页数:8
相关论文
共 38 条
[11]   The consortium to establish a registry for Alzheimer's disease (CERAD) .14. Demographic and clinical predictors of survival in patients with Alzheimer's [J].
Heyman, A ;
Peterson, B ;
Fillenbaum, G ;
Pieper, C .
NEUROLOGY, 1996, 46 (03) :656-660
[12]   Aβ immunization and anti-Aβ antibodies:: potential therapies for the prevention and treatment of Alzheimer's disease [J].
Holtzman, DM ;
Bales, KR ;
Paul, SM ;
DeMattos, RB .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (12) :1603-1613
[13]   Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo:: evidence for augmentation of a 42-specific γ secretase [J].
Jankowsky, JL ;
Fadale, DJ ;
Anderson, J ;
Xu, GM ;
Gonzales, V ;
Jenkins, NA ;
Copeland, NG ;
Lee, MK ;
Younkin, LH ;
Wagner, SL ;
Younkin, SG ;
Borchelt, DR .
HUMAN MOLECULAR GENETICS, 2004, 13 (02) :159-170
[14]   Transgenic mouse models of Alzheimer's disease [J].
Janus, C ;
Westaway, D .
PHYSIOLOGY & BEHAVIOR, 2001, 73 (05) :873-886
[15]  
Jensen M, 1999, ANN NEUROL, V45, P504, DOI 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO
[16]  
2-9
[17]  
Johnson D, 1997, EDN, V42, P94
[18]   Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease [J].
Kawarabayashi, T ;
Younkin, LH ;
Saido, TC ;
Shoji, M ;
Ashe, KH ;
Younkin, SG .
JOURNAL OF NEUROSCIENCE, 2001, 21 (02) :372-381
[19]   The load and distribution of β-amyloid in brain tissue of patients with Alzheimer's disease [J].
Kraszpulski, M ;
Soininen, H ;
Helisalmi, S ;
Alafuzoff, I .
ACTA NEUROLOGICA SCANDINAVICA, 2001, 103 (02) :88-92
[20]   Biochemical diagnostic markers to detect early Alzheimer's disease [J].
Lannfelt, L .
NEUROBIOLOGY OF AGING, 1998, 19 (02) :165-167